Asmanex/Foradil combo development
Schering-Plough and Novartis will develop Asmanex/Foradil combination product to treat asthma and chronic obstructive pulmonary disorder, the companies announced April 10. Schering's pending NDA for Asmanex (mometasone) was submitted Nov. 30, 1998. In November 2002, Schering acquired U.S. marketing rights to Novartis' Foradil (formoterol) (1"The Pink Sheet" Nov. 4, 2002, p. 22)...
You may also be interested in...
Schering-Plough is plugging a hole in its asthma product line by in-licensing Novartis' Foradil
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
The HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.